<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJPathology</journal-id><journal-title-group><journal-title>Open Journal of Pathology</journal-title></journal-title-group><issn pub-type="epub">2164-6775</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojpathology.2024.142007</article-id><article-id pub-id-type="publisher-id">OJPathology-132041</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Intraductal Prostatic Carcinoma: Epidemiological and Anatomopathological Aspects in Dakar
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ibou</surname><given-names>Thiam</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fabrice</surname><given-names>Senghor</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Omar</surname><given-names>Sow</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kor</surname><given-names>Ndiaye</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohamed</surname><given-names>Moustapha Chérif Dial</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>General Surgery Department, Peace Hospital, Ziguinchor, Senegal</addr-line></aff><aff id="aff2"><addr-line>Anatomical Pathology Department, Peace Hospital, Ziguinchor, Senegal</addr-line></aff><aff id="aff1"><addr-line>Anatomical Pathology Department, Aristide Le Dantec University Hospital, Dakar, Senegal</addr-line></aff><aff id="aff4"><addr-line>Anatomical Pathology Department, Idrissa Pouye University Hospital, Dakar, Senegal</addr-line></aff><pub-date pub-type="epub"><day>22</day><month>02</month><year>2024</year></pub-date><volume>14</volume><issue>02</issue><fpage>54</fpage><lpage>63</lpage><history><date date-type="received"><day>16,</day>	<month>January</month>	<year>2024</year></date><date date-type="rev-recd"><day>24,</day>	<month>March</month>	<year>2024</year>	</date><date date-type="accepted"><day>27,</day>	<month>March</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial International License (CC BY-NC).http://creativecommons.org/licenses/by-nc/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: Intraductal carcinoma is often associated with high-grade, high-stage adenocarcinoma. Its frequency is variable and it is considered a poor prognostic factor. In our context, when prostatic carcinoma is diagnosed, pathologists do not always report the presence of this anatomopathological entity. We therefore conducted a study to determine the epidemiological and anatomopathological profile of patients with this lesion in Dakar. 
  Materials and Methods: This is a retrospective descriptive study covering a 1-year period from January to December 2022. It focused on cases of intraductal carcinoma diagnosed among prostatic carcinomas collected in the anatomopathology laboratories of H
  &amp;#244;pital G&#233;n&#233;ral Idrissa Pouye (HOGIP) and H
  &amp;#244;pital Militaire de Ouakam (HMO). It was based on archives of anatomopathological reports, blocks and slides. A total of 200 cases of prostatic carcinoma were collated and reviewed to identify those presenting with intraductal carcinoma according to the diagnostic criteria of Guo and Epstein. 
  Results: 87 cases of intraductal carcinoma were found, representing 43.5% of prostatic carcinomas. The mean age was 71 years. Patients in their seventh decade were the most represented, 
  <em>i.e.</em> 42.5%. The majority of samples examined were biopsies (72.4%). The mean PSA level was 965.91 ng/ml, with extremes ranging from 0.03 to 10,000 ng/ml. Histologically, 96.5% of cases (N = 84) were invasive prostatic carcinoma. Gleason score 8 (4 + 4) was the most common, accounting for 42.53% (N = 37). On average, the study found four (04) foci of intraductal carcinoma per specimen, with extremes ranging from 1 to 30. Dense cribriform architecture accounted for 78.16%, loose cribriform for 11.5%, solid for 8.04% and micropapillary for 2.3%. Six cases (6.9%) showed foci of comedonecrosis. The vast majority of radical prostatectomies (87.5%) were classified as pT3. Node invasion and perineural sheathing were observed in 12.5% and 52.32% of cases respectively. 
  Conclusion: Intraductal carcinoma is a poor prognostic factor that must be systematically reported in the anatomopathological report. In Senegal, it is often associated with advanced stage, high-grade carcinoma and high PSA levels.
 
</p></abstract><kwd-group><kwd>Intraductal Carcinoma</kwd><kwd> Prostate</kwd><kwd> Pathological Anatomy</kwd><kwd> Senegal</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>According to the WHO, intraductal prostatic carcinoma (IDC-P is defined as an intra-acinar and/or intraductal neoplastic proliferation presenting certain characteristics of high-grade intraepithelial neoplasia (PIN) but including cytological and architectural abnormalities much more marked. It is considered a poor prognostic factor often associated with adenocarcinoma of high grade, stage and Gleason score, increased prostate volume, extra-prostatic invasion and metastases [<xref ref-type="bibr" rid="scirp.132041-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref2">2</xref>] . Similarly, several studies have reported lower cancer-specific and overall progression-free survival in affected patients [<xref ref-type="bibr" rid="scirp.132041-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref4">4</xref>] . Current theories on the histogenesis of this pathology suggest that a large proportion of these lesions represent an adenocarcinoma with retrograde invasion into the prostate ducts [<xref ref-type="bibr" rid="scirp.132041-ref5">5</xref>] . The frequency of this pathology varies greatly (from 2% to 67%) depending on the studies and their own sampling [<xref ref-type="bibr" rid="scirp.132041-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref7">7</xref>] . Prostate cancer remains a pathology diagnosed late, often at an advanced stage, with an increasing incidence in Senegal [<xref ref-type="bibr" rid="scirp.132041-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref9">9</xref>] . In this same country, intraductal carcinoma is almost not reported in the pathological results of invasive prostate cancer, when it is present. Moreover, no study was found in black Africa, particularly in Senegal on intraductal carcinoma of the prostate. We therefore conducted a study aimed at evaluating the frequency of this entity in subjects presenting with prostate carcinoma in Dakar (Senegal), then to describe the epidemiological and anatomopathological characteristics.</p></sec><sec id="s2"><title>2. Materials and Methods</title><p>This is a retrospective descriptive study over a period of one year, from January 1 to December 31, 2022. The study took place in the anatomopathology laboratories of the Idrissa Pouye General Hospital (HOGIP) and the Ouakam Military Hospital (HMO). The selection of patients was carried out from registers and reports of archived anatomopathological examinations of cases of prostate carcinoma. The archived histological slides of the selected cases were then reread, in order to look for the presence of foci of intraductal carcinoma.</p><p>The data were collected in the same way, by telephone interview, from the histological examination reports and after rereading the slides, in an Excel collection file. The study parameters were: age, prostate specific antigen (PSA) level, type of sample, Gleason score, presence of nerve invasion, foci of intraductal carcinoma and comedonecrosis, predominant architecture, pT stage and metastases. After re-reading, all patients with histologically confirmed intraductal carcinoma were included (i.e. N = 87), whether they were associated with an infiltrating carcinoma or not.</p></sec><sec id="s3"><title>3. Procedure</title><p>Firstly, a collection of 560 prostate sample identifiers was made.</p><p>Then an analysis of the corresponding histological examination protocols and reports made it possible to identify 200 prostate carcinomas. Finally, we carried out a double re-reading of the archive slides by senior pathologists.</p><p>The identification of intraductal carcinoma was based on the criteria defined by Guo CC and Epstein JI [<xref ref-type="bibr" rid="scirp.132041-ref10">10</xref>] : intraductal proliferation with the presence of basal cells in the periphery with:</p><p>Major criteria (the presence of a single one makes the diagnosis)</p><p>- Dense cribriform architecture (cells occupy at least 50% of the lumen) or solid (<xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="fig" rid="fig2">Figure 2</xref>);</p><p>- Loose cribriform architecture (cells occupy less than 50% of the lumen) or micropapillary architecture with markedly enlarged nuclei (6 times normal) (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig4">Figure 4</xref>);</p><p>- Non-focal comedonecrosis.</p><p>Minor criteria</p><p>- At least 6 glands involved;</p><p>- Irregularly shaped glands with right-angled branching;</p><p>- Frequent/easily identifiable mitoses;</p><p>- Two (2) cell populations (mitotically active at the periphery and quiescent cells at the center).</p><p>Data entry and analysis was carried out with EPI-INFO software version 7.2.6 and Microsoft Excel 2010. For the descriptive analysis, the qualitative variables were described by frequency tables. The quantitative variables were described by their position (average, median) and dispersion (standard deviation, extremes) parameters.</p></sec><sec id="s4"><title>4. Results</title><p>During the study period we identified 200 cases of prostate carcinoma. After re-reading, 87 cases of intraductal carcinoma were found, i.e. a frequency of 43.5%.</p><p>The average age was 71.5 years with a standard deviation of 8.83, a median of 72 years and extremes of 52 and 91 years. Patients in the seventh decade were the most represented, i.e. 42.5%, followed by those in the sixth decade aged 60 - 69 (30%) (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><p>The average total PSA level was 965.91 ng/ml with a standard deviation of 1785.8, a median of 200 ng/ml and extremes of 0.03 and 10,000 ng/ml. The cohort was mainly made up of biopsy samples, i.e. 72.41% (N = 63), followed by transurethral resections of the prostate (TURP) representing 17.24% (N = 15) (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of absolute and relative frequencies of Gleason score sampling types, predominant IDC-P architecture, T class</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Workforce (N)</th><th align="center" valign="middle" >Frequency (%)</th></tr></thead><tr><td align="center" valign="middle" >Sampling (N = 87)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Biopsy</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >72.41</td></tr><tr><td align="center" valign="middle" >TURP</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >17.24</td></tr><tr><td align="center" valign="middle" >Radical prostatectomy</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >9.20</td></tr><tr><td align="center" valign="middle" >Adenomectomy</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.15</td></tr><tr><td align="center" valign="middle" >Gleason Score (N = 84)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >6 (3 + 3)</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >4.76</td></tr><tr><td align="center" valign="middle" >7 (3 + 4)</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >22.62</td></tr><tr><td align="center" valign="middle" >7 (4 + 3)</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >21.43</td></tr><tr><td align="center" valign="middle" >8 (4 + 4)</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >44.05</td></tr><tr><td align="center" valign="middle" >≥9</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >7.14</td></tr><tr><td align="center" valign="middle" >IDC-P architecture (N = 87)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Dense cribriform</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >78.16</td></tr><tr><td align="center" valign="middle" >Solid</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8.04</td></tr><tr><td align="center" valign="middle" >Loose cribriform</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >11.5</td></tr><tr><td align="center" valign="middle" >Micro-papillary</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.3</td></tr><tr><td align="center" valign="middle" >Class (N = 8)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >12.5</td></tr><tr><td align="center" valign="middle" >T3 a</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >62.5</td></tr><tr><td align="center" valign="middle" >T3 b</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >25</td></tr></tbody></table></table-wrap><p>Histologically, 96.5% of cases (n = 84) corresponded to invasive prostatic carcinoma. The Gleason score 8 (4 + 4) was the most represented, i.e. 44.05% (n = 37) (<xref ref-type="table" rid="table1">Table 1</xref>). Only 3.45% (n = 3) of the samples showed an isolated intraductal adenocarcinoma without an invasive focus. An average of 4.3 foci of intraductal carcinoma were identified on the samples with a standard deviation of 4.9, a median of 3 and extremes of 1 to 30.</p><p>The dense cribriform architecture was largely predominant, i.e. 78.16% (n = 68 cases) (<xref ref-type="table" rid="table1">Table 1</xref>). Comedonecrosis was observed in six cases, i.e. 6.9%, all having Gleason scores 8 and 9, and dense or solid cribriform architecture. The vast majority of radical prostatectomies (87.5%) were classified as pT3 and lymph node invasion was observed in 12.5% of cases (n = 1) (<xref ref-type="table" rid="table1">Table 1</xref>). Perineural sheathing was observed in 56.32% of the cohort (n = 49 cases). No distant metastases have been documented.</p></sec><sec id="s5"><title>5. Discussion</title><p>Intraductal carcinoma was described in prostate cancers in 1985 and was only recognized as a diagnostic entity in 2016 by the WHO, which included it in its classification [<xref ref-type="bibr" rid="scirp.132041-ref10">10</xref>] . Its frequency varies widely depending on patient cohorts. It is 2% to 3% in patients at low metastatic risk and 67% for those at high risk or with confirmed metastasis [<xref ref-type="bibr" rid="scirp.132041-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref12">12</xref>] . In our series, IDC-P represented 43.5%, associated in a large majority (49%) with high-grade invasive carcinoma (Gleason score 8 or 9). This frequency could be explained by the fact that prostate cancer in Senegal is often high grade, diagnosed at an advanced, metastatic stage [<xref ref-type="bibr" rid="scirp.132041-ref9">9</xref>] . These data support the relationship between the presence of this anatomopathological entity and the aggressiveness of prostate cancer [<xref ref-type="bibr" rid="scirp.132041-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref7">7</xref>] . Isolated intraductal carcinoma, without an associated focus of invasive carcinoma, is rare. Its frequency varies widely in the literature. It is less than 1% in several large studies with large biopsy cohorts [<xref ref-type="bibr" rid="scirp.132041-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref10">10</xref>] , but 10% in the study by Brian. D et al. concerning radical prostatectomies [<xref ref-type="bibr" rid="scirp.132041-ref13">13</xref>] . Our series finds an IDC-P percentage of 3.4%. This result could be explained by the fact that our cohort is made up of mixed samples, the vast majority biopsy (72.4%).</p><p>Conventional IDC-P (IDC-P with invasive carcinoma) would represent retrograde spread of high-grade invasive acinic carcinoma, into the prostatic ducts and acini. It is associated with poor prognosis criteria for radical prostectomies [<xref ref-type="bibr" rid="scirp.132041-ref2">2</xref>] . While studies would suggest that isolated IDC-P or IDC-P with low-grade adenocarcinoma may represent a de novo precursor lesion associated with better prognosis [<xref ref-type="bibr" rid="scirp.132041-ref2">2</xref>] . These entities are currently pathologically indistinguishable [<xref ref-type="bibr" rid="scirp.132041-ref2">2</xref>] .</p><p>Patients with classic adenocarcinoma of the prostate are generally over 50 years old with an average age close to 70 years, as found in our work and several studies [<xref ref-type="bibr" rid="scirp.132041-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref14">14</xref>] . This observation, found in several states in sub-Saharan Africa, could be due to the delay in consulting patients and the absence of systematic screening from the age of 45 - 50 [<xref ref-type="bibr" rid="scirp.132041-ref9">9</xref>] .</p><p>Studies find that patients with prostate carcinoma with IDC-P have higher PSA levels than their counterparts without IDC-P, although there is no statistically significant correlation [<xref ref-type="bibr" rid="scirp.132041-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref15">15</xref>] .</p><p>The PSA level is correlated with the clinical stage [<xref ref-type="bibr" rid="scirp.132041-ref16">16</xref>] , it increases with the extension of the disease. Prostate cancer in black Africa is frequently associated with a significant elevation in PSA, often greater than 10 times normal, as corroborated by our work (median PSA = 200 ng/ml) as well as several West African studies [<xref ref-type="bibr" rid="scirp.132041-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref19">19</xref>] . This result confirms the diagnostic delay (a long evolution of the disease before diagnosis).</p><p>An average of four (04) foci of intraductal carcinoma were identified on the samples. Most of our cases fulfilled the major criteria (architecture, cytonuclear atypia) and to a lesser extent comedonecrosis.</p><p>Dense cribriform architecture was largely predominant, accounting for 78.16%, followed by loose (11.5%) and solid (8.04%) cribriform architecture. These results are similar to those of Guo CC [<xref ref-type="bibr" rid="scirp.132041-ref10">10</xref>] who found 68% cribriform. According to several authors, “dense cribriform” and solid patterns as well as the presence of comedonecrosis have a poorer prognosis [<xref ref-type="bibr" rid="scirp.132041-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref20">20</xref>] . The six cases in our series who presented with comedonecrosis had a dense or solid cribriform architecture and a Gleason score 8 or 9, indicating a poor prognosis.</p><p>Perineural invasion is a major prognostic factor and especially predictive of metastasis [<xref ref-type="bibr" rid="scirp.132041-ref21">21</xref>] . It varies considerably depending on the types of patients and samples, but especially depending on the Gleason grade. It is higher in radical prostatectomy cohorts than in biopsy cohorts, as well as among high-grade carcinomas [<xref ref-type="bibr" rid="scirp.132041-ref7">7</xref>] .</p><p>Its prevalence is increased in invasive carcinomas with IDC-P, as evidenced by the study by Saeter T [<xref ref-type="bibr" rid="scirp.132041-ref4">4</xref>] which found a twice as high proportion of perineural invasion, in patients with invasive carcinoma associated with IDC-P (72%) compared to their counterpartwithout IDC-P (39%), this difference being statistically significant. This same author highlighted a close relationship between IDC-P and the stromal reaction which will play a determining role in the promotion of tumor invasion facilitating perineural sheathing [<xref ref-type="bibr" rid="scirp.132041-ref4">4</xref>] . Invasive carcinomas associated with IDC-P are often high grade [<xref ref-type="bibr" rid="scirp.132041-ref22">22</xref>] and of advanced clinical stage cT3-4 (particularly following radical prostatectomy) [<xref ref-type="bibr" rid="scirp.132041-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref23">23</xref>] . Thus the type of sample, the invasive nature, the high grade and stage could explain the proportion of perineural invasion in our study (56.3%). This proportion is higher than that of biopsy series, notably Cohn [<xref ref-type="bibr" rid="scirp.132041-ref24">24</xref>] (8.5%) and Ahmad [<xref ref-type="bibr" rid="scirp.132041-ref25">25</xref>] (29.14%) and is closer to that of Zereba P. [<xref ref-type="bibr" rid="scirp.132041-ref26">26</xref>] (44%), Lee JT. [<xref ref-type="bibr" rid="scirp.132041-ref27">27</xref>] (52.1%), being series relating to prostatectomies.</p><p>Lymph node invasion is a poor prognostic factor and several authors maintain that the presence of an intraductal carcinoma associates a greater risk of lymph node metastasis [<xref ref-type="bibr" rid="scirp.132041-ref21">21</xref>] . Among our patients, 12.5% had lymph node involvement, this low proportion being explained by the low proportion of surgical specimens in our cohort.</p><p>Among patients with invasive prostate carcinoma, those associated with IDC-P have an increased risk of metastases [<xref ref-type="bibr" rid="scirp.132041-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.132041-ref3">3</xref>] . The bones, particularly the vertebrae, are the predilection sites for metastatic prostate carcinoma [<xref ref-type="bibr" rid="scirp.132041-ref10">10</xref>] .</p></sec><sec id="s6"><title>6. Limitations of the Study</title><p>This work could present limits which we were able to identify as follows.</p><p>- This was a retrospective study.</p><p>- Our study was limited to determining the epidemiological and anatomopathological profile of intraductal carcinoma in Senegal.</p><p>- We were unable to carry out the immunohistochemistry and molecular biology techniques which would have allowed respectively better diagnostic accuracy, and molecular typing.</p><p>- We were unable to have the necessary hindsight to assess the prognosis and precisely the survival of our patients given the duration of the study and missing information. Nevertheless, our study presents positive points.</p><p>- This is a multicenter study and the first focusing on intraductal prostatic carcinomas to our knowledge in Senegal, hence its originality.</p><p>- It was carried out in the cosmopolitan city of Dakar where we find the populations of all origins, with the contribution of the Pathological Anatomy and Cytology laboratories of a university hospital and the Ouakam Military Hospital, all of which polarizes a large part of the urological samples.</p></sec><sec id="s7"><title>7. Conclusion</title><p>In Senegal, intraductal carcinoma is often associated with invasive carcinoma of the prostate as well as poor prognostic factors, such as high grade, advanced stage, and high PSA level. It is necessary to mention its presence in all pathological reports. In perspective, a prospective study with study of molecular alterations and an evaluation of patient survival according to therapeutic regimens, will allow a good assessment of its prognostic impact and better management.</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s9"><title>Cite this paper</title><p>Thiam, I., Senghor, F., Sow, O., Ndiaye, K. and Dial, M.M.C. (2024) Intraductal Prostatic Carcinoma: Epidemiological and Anatomopathological Aspects in Dakar. Open Journal of Pathology, 14, 54-63. https://doi.org/10.4236/ojpathology.2024.142007</p></sec></body><back><ref-list><title>References</title><ref id="scirp.132041-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Humphrey, P.A., Moch, H., Cubilla, A.L., Ulbright, T.M. and Reuter, V.E. (2016) The 2016 WHO Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumors. European Urology, 70, 106-119. https://doi.org/10.1016/j.eururo.2016.02.028</mixed-citation></ref><ref id="scirp.132041-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Szentirmai, E. and Giannico, G.A. (2020) Intraductal Carcinoma of the Prostate. Pathologica—Journal of the Italian Society of Anatomic Pathology and Diagnostic Cytopathology, 112, 17-24. https://doi.org/10.32074/1591-951X-5-20</mixed-citation></ref><ref id="scirp.132041-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kato, M., Kimura, K., Hirakawa, A., et al. (2018) Prognostic Parameter for High Risk Prostate Cancer Patients at Initial Presentation. Prostate, 78, 11-16. https://doi.org/10.1002/pros.23438</mixed-citation></ref><ref id="scirp.132041-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Saeter, T., Vlatkovic, L., Waaler, G., et al. (2017) Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study. Prostate, 77, 859-865. https://doi.org/10.1002/pros.23326</mixed-citation></ref><ref id="scirp.132041-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Haffner, M.C., Weier, C., Xu, M.M., et al. (2016) Molecular Evidence That Invasive Adenocarcinoma Can Mimic Prostatic Intraepithelial Neoplasia (PIN) and Intraductal Carcinoma through Retrograde Glandular Colonization. The Journal of Pathology, 238, 31-41. https://doi.org/10.1002/path.4628</mixed-citation></ref><ref id="scirp.132041-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Watts, K., Li, J., Magi-Galluzzi, C. and Zhou, M. (2013) incidence and Clinicopathological Characteristics of Intraductal Carcinoma Detected in Prostate Biopsies: A Prospective Cohort Study. Histopathology, 63, 574-579. https://doi.org/10.1111/his.12198</mixed-citation></ref><ref id="scirp.132041-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y.C., Sun, G.L., Ma, D.L., et al. (2020) The Presence of Intraductal Carcinoma of the Prostate Is Closely Associated with Poor Prognosis: A Systematic Review and Meta-Analysis. Asian Journal of Andrology, 23, 103-108. https://doi.org/10.4103/1008-682X.194817</mixed-citation></ref><ref id="scirp.132041-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ndoye, M., Niang, L., Gandaho, K.I., Jalloh, M., Labou, I. and Gueye, S. (2014) Advanced Prostate Cancer in Senegal. Diagnostic Aspects at Grand Yoff Hospital. Progress in Urology, 24, 271-275. https://doi.org/10.1016/j.purol.2013.08.317</mixed-citation></ref><ref id="scirp.132041-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ndiaye, M., Sow, O., Thiam, A., et al. (2020) Prostate Cancer at the Aristidie Le Dantec University Hospital Center in Dakar: Epidemiological Aspects over the Last Five Years. Annals of African Medicine, 14, E4004-E4009.</mixed-citation></ref><ref id="scirp.132041-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Guo, C.C. and Epstein, J.I. (2006) Intraductal Carcinoma of the Prostate on Needle Biopsy: Histologic Features and Clinical Significance. Modern Pathology, 19, 1528-1535. https://doi.org/10.1038/modpathol.3800702</mixed-citation></ref><ref id="scirp.132041-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Varshney, S., Buttirini, G. and Gupta, R. (2002) Incidental Carcinoma of the Gallbladder. European Journal of Surgical Oncology (EJSO), 28, 4-10. https://doi.org/10.1053/ejso.2001.1175</mixed-citation></ref><ref id="scirp.132041-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Varma, M., Delahunt, B., Egevad, L. and Samaratunga, H. (2019) Kristiansen Gintraductal Carcinoma of the Prostate: A Critical Re-Appraisal. Virchows Archiv, 474, 525-534. https://doi.org/10.1007/s00428-019-02544-6</mixed-citation></ref><ref id="scirp.132041-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Robinson, B.D. and Epstein, J.I. (2010) Intraductal Carcinoma of the Prostate without Invasive Carcinoma on Needle Biopsy: Emphasis on Radical Prostatectomy Findings. Journal of Urology, 184, 1328-1333. https://doi.org/10.1016/j.juro.2010.06.017</mixed-citation></ref><ref id="scirp.132041-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Sylla Niang, M., Drame, N., Jalloh, M., et al. (2010) Distribution of Prostate Specific Antigen in a Senegalese Population. Immuno-Analysis &amp; Specialized Biology, 25, 67-71. https://doi.org/10.1016/j.immbio.2010.03.006</mixed-citation></ref><ref id="scirp.132041-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kato, M., Hirakawa, A., Kobayashi, Y., et al. (2019) The Influence of the Presence of Intraductal Carcinoma of the Prostate on the Grade Group System’s Prognostic Performance. The Prostate, 79, 1065-1070. https://doi.org/10.1002/pros.23818</mixed-citation></ref><ref id="scirp.132041-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Gueye, S.M., Jalloh, M., Labou, I., Niang, L., Kane, R. and Ndoye, M. (2004) Clinical Profile of Prostate Cancer in Senegal. African Journal of Urology, 10, 203-207.</mixed-citation></ref><ref id="scirp.132041-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Loko, F., Hodonou, R., Akpaka, R., Hounnasso, P., Adisso, S. and Akpo, C. (2011) Predictive Value of PSA in the Diagnosis of Prostate Cancer in Beninese Subjects. International Journal of Biological and Chemical Sciences, 5, 515-523. https://doi.org/10.4314/ijbcs.v5i2.72096</mixed-citation></ref><ref id="scirp.132041-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Niang, L., Ndoye, M., Ouattara, A., et al. (2013) Prostate Cancer: What Treatment in Senegal? Progress in Urology, 23, 36-41. https://doi.org/10.1016/j.purol.2012.09.002</mixed-citation></ref><ref id="scirp.132041-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kabore, F.A., Zango, B., Sanou, A., Yameogo, C. and Kirakoya, B. (2011) Prostate Cancer Outcome in Burkina Faso. Infectious Agents and Cancer, 6, S6. https://doi.org/10.1186/1750-9378-6-S2-S6</mixed-citation></ref><ref id="scirp.132041-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Osiecki, R., Kozikowski, M., Sarecka-Hujar, B., Pyzlak, M. and Dobruch, J. (2023) Prostate Cancer Morphologies: Cribriform Pattern and Intraductal Carcinoma Relations to Adverse Pathological and Clinical Outcomes—Systematic Review and Meta-Analysis. Cancers, 15, Article No. 1372. https://doi.org/10.3390/cancers15051372</mixed-citation></ref><ref id="scirp.132041-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Lindberg, J., Kristiansen, A., Wiklund, P., Gr&amp;#246;nberg, H. and Egevad, L. (2015) Tracking the Origin of Metastatic Prostate Cancer. European Urology, 67, 819-822. https://doi.org/10.1016/j.eururo.2014.09.006</mixed-citation></ref><ref id="scirp.132041-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">McNeal, J.E. and Yemoto, C.E. (1996) Spread of Adenocarcinoma within Prostatic Ducts and Acini. Morphologic and Clinical Correlations. The American Journal of Surgical Pathology, 20, 802-814. https://doi.org/10.1097/00000478-199607000-00003</mixed-citation></ref><ref id="scirp.132041-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Dinerman, B.F., Khani, F., Golan, R., et al. (2017) Population-Based Study of the Incidence and Survival for Intraductal Carcinoma of the Prostate. Urologic Oncology: Seminars and Original Investigations, 35, 673.E9-673.E14. https://doi.org/10.1016/j.urolonc.2017.08.015</mixed-citation></ref><ref id="scirp.132041-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Cohn, J.A., Dangle, P.P., Wang, C.E., et al. (2014) The Prognostic Significance of Perineural Invasion and Race in Men Considering Active Surveillance. BJU International, 114, 75-80. https://doi.org/10.1111/bju.12463</mixed-citation></ref><ref id="scirp.132041-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Ahmad, A.S., Parameshwaran, V., Beltran, L., et al. (2018) Should Reporting of Peri-Neural Invasion and Extra Prostatic Extension Be Mandatory in Prostate Cancer Biopsies? Correlation with Outcome in Biopsy Cases Treated Conservatively. Oncotarget, 9, 20555-20562. https://doi.org/10.18632/oncotarget.24994</mixed-citation></ref><ref id="scirp.132041-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Zareba, P., Flavin, R., Isikbay, M., et al. (2017) Perineural Invasion and Risk of Lethal Prostate Cancer. Cancer Epidemiology, Biomarkers &amp; Prevention, 26, 719-726. https://doi.org/10.1158/1055-9965.EPI-16-0237</mixed-citation></ref><ref id="scirp.132041-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J.T., Lee, S., Yun, C.J., et al. (2010) Prediction of Perineural Invasion and Its Prognostic Value in Patients with Prostate Cancer. Korean Journal of Urology, 51, 745-751. https://doi.org/10.4111/kju.2010.51.11.745</mixed-citation></ref></ref-list></back></article>